Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy.
Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.
Azuma
H
H
Oshima
M
M
Ito
K
K
Okuno
A
A
Kawabata
I
I
Banba
K
K
Murahashi
H
H
Sekine
T
T
Kato
Y
Y
Ikebuchi
K
K
Ikeda
H
H
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014923:Wiskott-Aldrich Syndrome / Q000097:blood / Q000276:immunology* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2; D011994:Recombinant Proteins